Search
for
Sort by
Research 16
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Upadacitinib is effective in treating psoriasis combined with lichen planus: a case report
- Update: baricitinib for alopecia areata
- The role of janus kinases in the treatment of autoimmune skin diseases
- Janus Kinase inhibitors in dermatology: a review
- Farmácia da Cruz, Porto e Serviços Farmacêuticos do Hospital General Universitario Gregorio Marañón, Espanha
- Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation
- Baricitinib for the Treatment of Alopecia Areata
- Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review
- New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience